TIDMMDC
RNS Number : 6305G
Mediclinic International plc
27 July 2021
Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
ISIN: GB00B8HX8Z88
LEI: 2138002S5BSBIZTD5I60
(" Mediclinic ", or the " Company " or the "Group")
27 July 2021
NEW DIRECTOR APPOINTMENTS AND CHANGES TO BOARD COMMITTEES
Mediclinic, a leading diversified international private
healthcare services group, announces the appointment of two new
independent non-executive directors: Natalia Barsegiyan and Zarina
Bassa .
Dame Inga Beale, Chair of Mediclinic, commented: "The Board is
delighted to welcome Natalia and Zarina as independent
non-executive directors of the Company. Each will bring significant
and diverse skills and experience, complementing those of existing
Board members. I am confident they will both be great additions to
our Board of Directors."
Natalia Barsegiyan is currently a non-executive director of
Domino's Pizza Group plc, the FTSE 250 digitally-enabled, quick
service international restaurant group and is a member of their
Audit Committee. She also acts as an adviser to Kharis Capital, a
private equity firm based in Belgium. Prior to this, the majority
of Natalia's career was with the US group Yum! Brands, Inc., owner
of a portfolio of many well-known brands such as KFC, Pizza Hut and
Taco Bell, where she served as Chief Commercial Officer of the
Group and then Chief Financial Officer of Taco Bell. Her
appointment as a director of Mediclinic will become effective on 1
August 2021. Natalia will bring a strong finance background with a
commercial and strategic focus, an in-depth understanding of the
use of data analytics to support transformation and broad
international experience, having lived and worked across the US,
Europe, Russia and the UK.
Zarina Bassa is currently the senior independent director of
Investec plc and Investec Ltd, the specialist banking and wealth
management group with a dual listed company structure and listings
on the London and Johannesburg Stock Exchanges; lead independent
director of Woolworths Holdings Ltd; and non-executive director of
JSE Ltd and Oceana Group Ltd (the last three all being South
African companies with a listing on the Johannesburg Stock
Exchange). Zarina has stepped down today as Chair of Yebo Yethu Ltd
and previously served as a non-executive director at several other
companies including Kumba Iron Ore Ltd; Mercedes Benz SA Ltd; Sun
International Ltd; Vodacom South Africa Proprietary Limited; the
South African Institute of Chartered Accountants; and the Financial
Services Board. Prior to that, she was a partner of Ernst &
Young Inc. and then joined the Absa Group in 2002, where she served
as an executive director of Absa Bank, a member of the group's
executive committee, and Head of the Private Bank. Zarina's
appointment as a director of Mediclinic will become effective on 1
February 2022. The Board of Mediclinic has carefully considered
Zarina's existing time commitments and is satisfied that she will
have sufficient time to dedicate to fulfil her responsibilities to
the Group. She will contribute strategic and operational experience
in complex, regulated environments, a strong financial and
accounting background, and diverse experience in listed companies
across a breadth of sectors and jurisdictions.
CHANGES TO BOARD COMMITTEES
Following a review of the Board Committee structure and
responsibilities, the Board has decided to separate the
responsibilities of the Clinical Performance and Sustainability
Committee, to allow for more time to dedicate to the oversight of
these key aspects of the Group's strategy and operations.
Accordingly, with effect from 1 September 2021:
-- the Clinical Performance and Sustainability Committee will become a focused Clinical Performance Committee. There
will be no change in its composition; and
-- a new Environmental, Social and Governance Committee will be established, chaired by Dame Inga, with other
members comprising: Dr Ronnie van der Merwe, Natalia Barsegiyan, Dr Felicity Harvey and Danie Meintjes.
In addition:
-- Natalia Barsegiyan will also join the Audit and Risk Committee upon her appointment as a non-executive director;
-- Zarina Bassa will join the Audit and Risk and Remuneration Committees when her appointment as non-executive
director becomes effective;
-- Dr Muhadditha Al Hashimi will join the Remuneration Committee on 13 September 2021; and
-- Tom Singer will join the Investment Committee on 13 September 2021.
Other changes to roles and responsibilities of other directors
will also proceed as announced by the Company on 26 May 2021.
This announcement is made in accordance with the requirement of
LR 9.6.11. There are no disclosures required pursuant to paragraphs
(1) to (6) of LR 9.6.13 R of the United Kingdom Listing Authority's
Listing Rules in respect of these appointments.
About Mediclinic International plc
Mediclinic is a diversified international private healthcare
services group, established in South Africa in 1983, with divisions
in Switzerland, Southern Africa (South Africa and Namibia) and the
United Arab Emirates ("UAE").
The Group's core purpose is to enhance the quality of life.
Its vision is to be the partner of choice that people trust for
all their healthcare needs.
Mediclinic is focused on providing specialist-orientated,
multi-disciplinary services across the continuum of care in such a
way that the Group will be regarded as the most respected and
trusted provider of healthcare services by patients, medical
practitioners, funders and regulators of healthcare in each of its
markets.
At 1 July 2021, Mediclinic comprised 74 hospitals, five subacute
hospitals, two mental health facilities, 18 day case clinics and 18
outpatient clinics. Hirslanden operated 17 hospitals and four day
case clinics in Switzerland with more than 1 900 inpatient beds;
Mediclinic Southern Africa operations included 50 hospitals (three
of which in Namibia), five sub-acute hospitals, two mental health
facilities and 12 day case clinics (four of which operated by
Intercare) across South Africa, and around 8 600 inpatient beds;
and Mediclinic Middle East operated seven hospitals, two day case
clinics and 18 outpatient clinics with more than 900 inpatient beds
in the UAE. In addition, under management contracts, Mediclinic
Middle East operates one hospital in Abu Dhabi and will open a
200-bed hospital in the Kingdom of Saudi Arabia in mid-2022.
The Company's primary listing is on the LSE in the UK, with
secondary listings on the JSE in South Africa and the Namibian
Stock Exchange in Namibia.
Mediclinic also holds a 29.9% interest in Spire Healthcare Group
plc, a leading private healthcare group based in the United Kingdom
and listed on the LSE.
For further information, please contact:
Company Secretary, Link Company Matters Limited
Caroline Emmet
+44 (0)333 300 1930
Investor Relations, Mediclinic International plc
James Arnold, Head of Investor Relations
ir@mediclinic.com
+44 (0)20 3786 8181
Media queries
FTI Consulting
Ben Atwell/Ciara Martin - United Kingdom
+44 (0)20 3727 1000
Sherryn Schooling - South Africa
+27 (0)21 487 9000
Registered address: 6(th) Floor, 65 Gresham Street, London, EC2V
7NQ, United Kingdom
Website: www.mediclinic.com
Corporate broker (United Kingdom): Morgan Stanley & Co
International plc and UBS Investment Bank
JSE sponsor (South Africa): Rand Merchant Bank (A division of
FirstRand Bank Limited)
NSX sponsor (Namibia): Simonis Storm Securities (Pty) Ltd
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOAPPUAUMUPGGGM
(END) Dow Jones Newswires
July 27, 2021 09:00 ET (13:00 GMT)
Mediclinic (LSE:MDC)
Historical Stock Chart
From Apr 2024 to May 2024
Mediclinic (LSE:MDC)
Historical Stock Chart
From May 2023 to May 2024